NASDAQ · ESLAW
Healthcare · Biotechnology
$0.07
Down-$0.01 (-10.93%)
Updated Sep 13, 2026, 3:59 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 3 trading sessions · Daily adjusted prices
ESLAW closed at $0.07 after 3 trading sessions, down 10.87% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.0669 | $0.0669 | $0.0669 | $0.0669 | 101 |
| Aug 25, 2026 | $0.075 | $0.0775 | $0.075 | $0.0775 | 2.18K |
| Aug 24, 2026 | $0.075 | $0.075 | $0.0725 | $0.075 | 613 |
The latest Smart Investors Daily articles mentioning ESLAW.
ESLAW research
Company profile and research snapshot.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Aug 26, 2026
By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Business Update STARLIGHT I Dose Expansion Underway Estrella Immunopharma (NASDAQ: ESLA) is currently conducting the Phase 1/2 STARLIGHT-1 trial of EB103 in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). The company recently announced that the first patient was dosed in the expansion phase, following
Yahoo · Aug 3, 2026
EMERYVILLE, Calif., August 03, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a third clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory ("R/R") B-cell non-Hodgkin’s lymph
Yahoo · Jul 29, 2026
EMERYVILLE, Calif., July 29, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory ("R/R") B-cell non-Hodgkin’s lympho
Yahoo · Jul 24, 2026
EMERYVILLE, Calif., July 24, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been successfully dosed in the dose-expansion phase of its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with relapsed/refractory (
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ESLAW.
No results
No recent SID articles mention ESLAW.
